Access Pharmaceuticals ($ACCP) has landed a deal to provide its drug-delivery technology to an unnamed "major" developer of RNA-interference drugs. The deal covers use of Access's CobaCyte platform, which exploits vitamin B12's ability to be absorbed in cells to deliver treatments and its CobOral tech for oral drug delivery. Access is among a bevy of drug-delivery specialists that have been tapped to help developers of RNAi drugs, which are designed to silence disease genes, get their molecules to desired locations in the body. The trouble of getting RNAi drugs to specific cells has been a major hurdle to developers in the field. Release